EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study

Rushi Patel iD, Jacob Thompson iD, Namra Patel iD, Abhi C Lohana iD, Fnu Versha, Subhash Chander iD, Viral Patel iD, Juan Iribarren

Journal of Clinical Medicine · 18.07.2026 · 15 (14) · 5650

DOI: 10.3390/jcm15145650 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.07.2026. Verfasst von Rushi Patel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Baptist Hospitals of Southeast Texas, Beaumont, TX 77701, USA. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Fixed-dose triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) at high risk of exacerbations; however, direct comparative effectiveness data between available triple therapy regimens remain limited. We compared real-world clinical outcomes among adults with COPD receiving fluticasone furoate/vilanterol/umeclidinium (FF/VI/UMEC) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR).

Methods

We conducted a retrospective propensity score-matched cohort study using the TriNetX Research Network. Adults with a spirometrically confirmed diagnosis of COPD who received fluticasone furoate/vilanterol/umeclidinium (FF/VI/UMEC) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR) between July 2020 and August 2024 were included in the analysis. A 365-day landmark period was applied to establish maintenance therapy, with outcome follow-up beginning 1 year after treatment initiation. Patients were followed for outcomes through August 2025, the date of database analysis. After 1:1 propensity score matching, treatment groups were compared for COPD exacerbations, acute respiratory failure (ARF), hospitalization, and all-cause mortality using RR and Cox proportional hazards analyses.

Results

In matched cohorts, FF/VI/UMEC was associated with a significantly higher risk of COPD exacerbations (5.6% vs. 3.9%; RR 1.44; 95% CI 1.30–1.59; p < 0.001) and ARF (2.5% vs. 1.9%; RR 1.28; 95% CI 1.11–1.46; p < 0.001) compared with BUD/GLY/FOR. Time-to-event analyses demonstrated lower event-free probability for exacerbations (HR 1.35; (95% CI 1.21–1.50) and ARF (HR 1.15; (95% CI 1.00–1.32))). All-cause mortality was numerically higher in the FF/VI/UMEC cohort (5.2% vs. 4.7%; RR 1.09; 95% CI 1.00–1.19; p = 0.050); however, time-to-event analysis did not demonstrate a statistically significant difference. Hospitalization rates were similar between groups.

Conclusions

In this large propensity score-matched real-world cohort study, patients receiving BUD/GLY/FOR experienced lower rates of COPD exacerbations and acute respiratory failure than those receiving FF/VI/UMEC. Because of the retrospective observational nature of the analysis, these findings should be considered hypothesis-generating and require confirmation in prospective comparative effectiveness studies.

Schlagwörter

Stichwörter der Autor:innen

chronic obstructive pulmonary diseasecohort studypropensity score matchingreal-world evidencetriple therapy

Autor:innen und Institutionen

  • Department of Internal Medicine, Baptist Hospitals of Southeast Texas, Beaumont, TX 77701, USA.
  • Department of Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
  • Department of Medicine, GMERS Medical College and Hospital, Valsad 396001, Gujarat, India.
  • Department of Internal Medicine, WVU Camden Clark Medical Center, Parkersburg, WV 26101, USA.
  • Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, USA.

ORCID-Profile: Rushi Patel, Jacob Thompson, Namra Patel, Abhi C Lohana, Subhash Chander, Viral Patel

Zitieren

APA

Patel, R., Thompson, J., Patel, N., Lohana, A. C., Versha, F., Chander, S., Patel, V., & Iribarren, J. (2026). Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study. Journal of Clinical Medicine, 15(14), 5650. https://doi.org/10.3390/jcm15145650

Vancouver

Patel R, Thompson J, Patel N, Lohana AC, Versha F, Chander S, et al. Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study. Journal of Clinical Medicine. 2026;15(14):5650. doi:10.3390/jcm15145650

BibTeX
@article{Patel2026,
  author = {Patel, Rushi and Thompson, Jacob and Patel, Namra and Lohana, Abhi C and Versha, Fnu and Chander, Subhash and Patel, Viral and Iribarren, Juan},
  title = {Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {14},
  pages = {5650},
  doi = {10.3390/jcm15145650}
}
Kostenlos starten →